Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance

<p><strong>Background:</strong><br /> Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. This study evaluated the efficacy and safety of tofacitinib 5 mg twice daily monotherapy after methotrex...

Full description

Bibliographic Details
Main Authors: Nash, P, Mease, PJ, Fleishaker, D, Wu, J, Coates, LC, Behrens, F, Gladman, DD, Kivitz, AJ, Wei, JC, Shirinsky, I, Menon, S, Romero, AB, Fallon, L, Hsu, MA, Wang, C, Kanik, KS
Format: Journal article
Language:English
Published: Elsevier 2020

Similar Items

Similar Items